Vigil Neuroscience Inc (VIGL) - Total Assets
Based on the latest financial reports, Vigil Neuroscience Inc (VIGL) holds total assets worth $86.70 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Vigil Neuroscience Inc - Total Assets Trend (2020–2024)
This chart illustrates how Vigil Neuroscience Inc's total assets have evolved over time, based on quarterly financial data. Also see Vigil Neuroscience Inc stock valuation for the company's overall valuation and market capitalisation.
Vigil Neuroscience Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Vigil Neuroscience Inc's total assets of $86.70 Million consist of 85.5% current assets and 14.5% non-current assets. Review debt load of Vigil Neuroscience Inc to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 33.2% |
| Accounts Receivable | $599.00K | 0.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Vigil Neuroscience Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of Vigil Neuroscience Inc for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vigil Neuroscience Inc's current assets represent 85.5% of total assets in 2024, a decrease from 100.0% in 2020.
- Cash Position: Cash and equivalents constituted 33.2% of total assets in 2024, down from 95.5% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 0.5% of total assets.
Vigil Neuroscience Inc Competitors by Total Assets
Key competitors of Vigil Neuroscience Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Vigil Neuroscience Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.06 | 8.39 | 12.68 |
| Quick Ratio | 2.06 | 8.39 | 12.68 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $36.18 Million | $79.46 Million | $23.30 Million |
Vigil Neuroscience Inc - Advanced Valuation Insights
This section examines the relationship between Vigil Neuroscience Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.11 |
| Latest Market Cap to Assets Ratio | 3.19 |
| Asset Growth Rate (YoY) | -16.4% |
| Total Assets | $117.69 Million |
| Market Capitalization | $375.71 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Vigil Neuroscience Inc's assets at a significant premium (3.19x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Vigil Neuroscience Inc's assets decreased by 16.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Vigil Neuroscience Inc (2020–2024)
The table below shows the annual total assets of Vigil Neuroscience Inc from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $117.69 Million | -16.45% |
| 2023-12-31 | $140.86 Million | -29.71% |
| 2022-12-31 | $200.39 Million | +95.62% |
| 2021-12-31 | $102.44 Million | +304.97% |
| 2020-12-31 | $25.30 Million | -- |
About Vigil Neuroscience Inc
Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain in the United States. The company's lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells… Read more